ClinicalTrials.gg
CompletedNCT01657552Updated Nov 13, 2017

Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

A Phase 1 interventional study of Eltrombopag and Boceprevir in Thrombocytopaenia, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.

Enrollment
23rd of 53
56 · median 40
Started
2012
with 7 others
Phase 1
8 of 53
none open now
Registered
34th of 53
by date
Lead sponsor
16 of 53
GlaxoSmithKline

Among the 53 studies testing eltrombopag in Thrombocytopenia, this one is the 23rd largest by enrollment, is one of 8 that started in 2012, is one of 8 in phase 1, and was the 34th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing eltrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

The purpose of the current Phase I, open-label, three-period, single sequence, crossover study, TPL116010, is to evaluate the potential drug-drug interaction between eltrombopag (ELT) and bocrprevir (BCP) and between ELT and telaprevir (TLP) in healthy subjects. In this study there will be a screening visit, three treatment periods, and a follow-up visit. In Period 1, subjects will receive a single dose of ELT on Day 1, and pharmacokinetic (PK) sampling will occur for 72 hours. In Period 2, subjects will receive BCP/TLP for 10 days with PK sampling for 8 hours. In Period 3, subjects will receive a single dose of ELT with BCP/TLP on Day 1 only with PK sampling for 72 hours. Subjects will return for a follow-up visit within 10 to 14 days of the last dose of study drugs. The total duration of the study from Screening to Follow-up will be approximately 9 weeks.

03

Conditions studied

  • Thrombocytopaenia

Browse trials for

Keywords

  • Drug interaction
  • INCIVEK (telaprevir),
  • SB-497115 (eltrombopag)
  • Pharmacokinetics
  • Thrombocytopenia
  • VICTRELIS (boceprevir)
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects with no abnormality identified by physician by evaluation of medical history, physical examination, clinical laboratory tests or (ECG).
  • Able to swallow and retain oral medication.
  • Male or female subjects between the ages of 18 to 64 years of age inclusive, at the time of signing the .
  • Capable of giving written informed consent which includes compliance with the requirements and restrictions listed in the consent form. Signed informed consent must be on file prior to screening procedures.
  • Body weight >= 50 kilogram (kg) (110 pounds [lbs]) for men and >=45 kg (99 lbs) for women and (BMI) of 18.5 to 32.0 kg/ (meters squared) m\^2 inclusive.
  • Male subjects, who are not surgically sterile, must agree on abstinence or to use a double barrier method, such as, a condom plus spermicidal agent (foam/gel/film/cream/suppository). This criterion must be followed from the time of the first dose of study medication until 14 days after the last dose of medication.
  • A female subject is eligible to participate if she is neither pregnant nor lactating, and falls into one of the following categories: non- including pre-menopausal females with documented (medical report verification) hysterectomy or bilateral oophorectomy, or females defined as being amenorrheic for greater than 1 year and having serum estradiol and follicle stimulating hormone levels consistent with menopause, child-bearing potential with negative beta human chorionic gonadotropin (βhCG) test and agrees to comply with recognized non-hormonal methods from screening or at least two weeks prior to first dose (whichever is earlier) until the follow-up visit. Recognized non-hormonal contraceptive methods include: complete abstinence from intercourse, two forms of barrier contraception (e.g. condom with spermicide, or diaphragm with spermicide), or intrauterine device (IUD).

Exclusion criteria

Exclusion Criteria:

  • History of Gilbert's syndrome.
  • History of deep vein thrombosis or other thromboembolic event.
  • History of thrombocytopenia or bleeding due to abnormal number or function.
  • Clotting factor abnormalities associated with hypercoagulability, including Factor V Leiden, Protein C or Protein S deficiency or antithrombin III deficiency.
  • Elevated blood pressure (BP) at screening, Day -1 and at pre-dose (systolic >140 mm Hg [millimeters of mercury], diastolic >90 mmHg). If the subject's BP is elevated on the first measurement, complete two additional BP measurements at least 2 minutes apart and average the three assessments to evaluate this criterion. If averaged BP exceeds the safety criteria, the subject should be excluded.
  • History of atrial fibrillation, mitral valve prolapse, significant heart murmur or vascular bruit.
  • Prolonged interval at screening, Day 1 and at pre-dose (for females and males >450 milliseconds [ms]). If the QTcF interval is prolonged on the initial , then complete two additional ECGs at least 5 minutes apart and take the average QTcF measurements of all three ECGs to evaluate this criterion. If averaged QTcF exceeds the safety criteria, the subject should be excluded.
  • Female subjects currently receiving hormone replacement therapy (HRT).
  • Positive for , virus infection or infection at screening.
  • Positive urine drug screen including serum alcohol at screening or pre-dose (Day -1).
  • History of alcohol/drug abuse or dependence within 12 months of the study. History of alcohol consumption in the past six months exceeding 7 units/week for women and 14 units/week for men (where 1 unit = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor).
  • Urinary cotinine levels indicative of smoking at screening or pre-dose (Day -1). History of regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Use of prescription or non-prescription drugs (including aspirin and non-steroidal anti-inflammatory drugs [NSAIDs]), vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer, such as St. John's Wort) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety.
  • Subjects who have donated plasma within 7 days prior to the screening visit or where participation in this study would result in donation of blood in excess of 500 milliliters (mL) within a 56-day period.
  • History of sensitivity to any of the study medications, or components thereof.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Eltrombopag

    Subjects will receive single oral dose of eltrombopag 200 mg in Period 1 with moderate-fat, low-calcium meal.

    Drug: Eltrombopag

  • Experimental
    Boceprevir

    Subjects will receive boceprevir 800 mg orally every 8 hours (hrs) for 10 days in Period 2 with moderate-fat meals.

    Drug: Boceprevir

  • Experimental
    Telaprevir

    Subjects will receive telaprevir 750 mg orally every 8 hours hrs for 10 days in Period 2 with moderate-fat meals.

    Drug: Telaprevir

  • Experimental
    Eltrombopag and Broceprevir

    Subjects will receive eltrombopag 200 mg as single oral dose and boceprevir 800 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.

    Drug: Eltrombopag · Drug: Boceprevir

  • Experimental
    Eltrombopag and Telaprevir

    Subjects will receive eltrombopag 200 mg as single oral dose and telaprevir 750 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.

    Drug: Eltrombopag · Drug: Telaprevir

Interventions

  • Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)

  • Each capsule contains 200 mg of Boceprevir (Dose 800 mg)

  • Each tablet contains 375 mg of Telaprevir (Dose 750 mg)

06

What researchers measure

Primary outcomes

  1. Composite pharmacokinetic (PK) parameters of eltrombopag following administration of boceprevir for 10 days with a single dose of eltrombopag

    Plasma eltrombopag PK Parameters: area under the concentration time-curves from time zero to infinity AUC(0-infinity) and maximum concentration (Cmax).

    Time frame: For 17 days

  2. Composite PK parameters of boceprevir following administration of boceprevir for 10 days with a single dose of eltrombopag

    Plasma boceprevir PK Parameters: AUC from time zero to the dosing interval AUC(0-τ), Cmax, and Concentraction at end of the dosing interval (Cτ)

    Time frame: For 17 days

  3. Composite PK parameters of eltrombopag following administration of telaprevir for 10 days with a single dose of eltrombopag

    Plasma eltrombopag PK Parameters: AUC(0-infinity) and Cmax

    Time frame: For 17 days

  4. Composite PK parameters of telaprevir following administration of telaprevir for 10 days with a single dose of eltrombopag

    Plasma telaprevir PK Parameters: AUC(0-τ), Cmax, and Cτ.

    Time frame: For 17 days

Secondary outcomes

  1. Composite PK parameters of eltrombopag following administration of boceprevir for 10 days with a single dose of eltrombopag

    Plasma eltrombopag PK Parameters: AUC from time zero to the last measurable concentration (AUC(0-t)), AUC obtained by extrapolation (%) (%AUCex), time from administration to first quantifiable concentration (tlag), time from administration to Cmax (tmax), elimination half life (t1/2), and apparent clearance (CL/F).

    Time frame: For 17 days

  2. Composite PK parameters of boceprevir following administration of boceprevir for 10 days with a single dose of eltrombopag

    Plasma boceprevir PK Parameter: tmax.

    Time frame: For 17 days

  3. Composite PK parameters of eltrombopag following administration of telaprevir for 10 days with a single dose of eltrombopag

    Plasma eltrombopag PK Parameters: AUC(0-t), %AUCex, tlag, tmax, t1/2, and CL/F.

    Time frame: For 17 days

  4. Composite PK parameters of telaprevir following administration of telaprevir for 10 days with a single dose of eltrombopag

    Plasma telaprevir PK Parameter: tmax.

    Time frame: For 17 days

  5. Safety and tolerability as assessed by the collection of adverse events

    Time frame: For 28 days

  6. Safety and tolerability as assessed by change from baseline in clinical laboratory tests

    Clinical laboratory tests include hematology, clinical chemistry, urinalysis tests.

    Time frame: For 28 days

  7. Safety and tolerability as assessed by change from baseline in vital sign

    Vital sign measurements will include systolic and diastolic blood pressure and pulse rate.

    Time frame: For 28 days

07

Study locations

1 site
  • GSK Investigational Site
    Baltimore, Maryland 21225, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Oct 2012, 2 months.

Of 18 phase 1 interventional studies under Thrombocytopenia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2012
First posted
Aug 6, 2012
StartActual
Aug 1, 2012
Primary completionActual
Oct 26, 2012
CompletionActual
Oct 26, 2012
Last update
Nov 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01657552
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 6, 2012
Start date
Aug 1, 2012
Primary completion
Oct 26, 2012
Completion
Oct 26, 2012
Last update
Nov 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eltrombopag · Boceprevir · Telaprevir

Start the discussion